Close Menu

research alliance

Researchers with the 11 hospitals in the RENACER network will work to molecularly characterize tissue samples and carry out basic and clinical studies.

The research may inform the use of a liquid biopsy assay for tracking SMM progression that improves on bone marrow aspirate analysis and is easier for patients to access.

The partnership aims to develop a test that will determine which patients with advanced colorectal cancer will not respond to standard treatment.

The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment.

The collaborators will work on advancing lung cancer antibodies that selectively target NRP2 isoforms, which have been linked to aggressive disease.

The team wants to create NK cell therapies from induced pluripotent stem cells and aims to achieve proof-of-concept for their technology in multiple myeloma.

The company will collaborate the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada.

Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.

A NorthShore University HealthSystem and Color pilot picked up pathogenic variants in nearly 9 percent of unselected individuals with a hereditary cancer gene test.